Literature DB >> 33558888

Dexmedetomidine attenuates lipopolysaccharide-induced acute liver injury in rats by inhibiting caveolin-1 downstream signaling pathway.

Fei Tong1, Wenchao Shen2, Pengtao Song3, Jiafeng Song3, Yonghe Hu1, Feifan Liu1, Zhipeng Meng1, Jing Liu4.   

Abstract

OBJECTIVE: The aim of the present study is to investigate the anti-injury and anti-inflammatory effects of dexmedetomidine (Dex) in acute liver injury induced by lipopolysaccharide (LPS) in Sprague-Dawley rats and its possible mechanism.
METHODS: The acute liver injury model of male rats was established by injecting LPS into tail vein. The mean arterial pressure (MAP) of rats was recorded at 0-7 h, and lactic acid was detected at different time points. Wet/dry weight ratio (W/D) was calculated. Pathological changes of rat liver were observed by HE staining. ALT and AST levels in serum were detected. The activities of myeloperoxidase (MPO) and superoxide dismutase (SOD) in liver tissue homogenate and the levels of IL-1β and IL-18 in serum were detected by ELISA. Protein levels of Caveolin-1 (Cav-1), TLR-4 and NLRP3 in liver tissue were tested by immunohistochemistry method. The expression of Cav-1, TLR-4 and NLRP3 mRNA in liver tissue was detected by quantitative polymerase chain reaction (qPCR) to explore its related mechanism.
RESULTS: Compared with NS group, serum lactic acid, W/D of liver tissue, MPO, SOD, IL-1β and IL-18 were significantly increased and MAP decreased significantly in LPS group and D+L group. However, compared with NS group, D group showed no significant difference in various indicators. Compared with LPS group, MPO, SOD, IL-1β and IL-18 were significantly decreased and MAP was significantly increased in D+L group. D+L group could significantly increase the level of Cav-1 protein and decrease the level of TLR-4 and NLRP3 protein in liver tissue caused by sepsis. The expression of Cav-1 mRNA was significantly up-regulated and the expression of TLR-4 and NLRP3 mRNA was inhibited in D+L group.
CONCLUSION: Dex pretreatment protects against LPS-induced actue liver injury via inhibiting the activation of the NLRP3 signaling pathway by up-regulating the expression of Cav-1 by sepsis.
© 2021 The Author(s).

Entities:  

Keywords:  Acute liver injury; Dexmedetomidine; Lipopolysaccharide; NLRP3; TLR-4

Mesh:

Substances:

Year:  2021        PMID: 33558888      PMCID: PMC7938455          DOI: 10.1042/BSR20204279

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  30 in total

1.  Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88.

Authors:  Shuhong Guo; Meghali Nighot; Rana Al-Sadi; Tarik Alhmoud; Prashant Nighot; Thomas Y Ma
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

2.  Hypoxic trophoblast HMGB1 induces endothelial cell hyperpermeability via the TRL-4/caveolin-1 pathway.

Authors:  Rongzhen Jiang; Jingjing Cai; Zhaowei Zhu; Dandan Chen; Jiemei Wang; Qingde Wang; Yincheng Teng; Yajuan Huang; Minfang Tao; Aibin Xia; Min Xue; Shenghua Zhou; Alex F Chen
Journal:  J Immunol       Date:  2014-10-22       Impact factor: 5.422

3.  Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection.

Authors:  Freddy A Medina; Cecilia J de Almeida; Elliott Dew; Jiangwei Li; Gloria Bonuccelli; Terence M Williams; Alex W Cohen; Richard G Pestell; Philippe G Frank; Herbert B Tanowitz; Michael P Lisanti
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 4.  Cisplatin-associated nephrotoxicity and pathological events.

Authors:  Takashi Taguchi; Arifa Nazneen; M Ruhul Abid; Mohammed S Razzaque
Journal:  Contrib Nephrol       Date:  2005       Impact factor: 1.580

5.  Dexmedetomidine attenuates lipopolysaccharide induced acute lung injury in rats by inhibition of caveolin-1 downstream signaling.

Authors:  Jing Liu; Xinhua Huang; Siping Hu; Huanzhong He; Zhipeng Meng
Journal:  Biomed Pharmacother       Date:  2019-08-10       Impact factor: 6.529

6.  Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts.

Authors:  Felipe Tapia Cáceres; Tracey A Gaspari; Chrishan S Samuel; Anita A Pinar
Journal:  FASEB J       Date:  2019-11-05       Impact factor: 5.191

7.  The effect of dexmedetomidine on inflammatory response of septic rats.

Authors:  Jianxing Zhang; Zhipeng Wang; Yan Wang; Guobin Zhou; Hongying Li
Journal:  BMC Anesthesiol       Date:  2015-05-01       Impact factor: 2.217

8.  Dexmedetomidine ameliorates acute lung injury following orthotopic autologous liver transplantation in rats probably by inhibiting Toll-like receptor 4-nuclear factor kappa B signaling.

Authors:  Xinjin Chi; Xiaoxia Wei; Wanling Gao; Jianqiang Guan; Xiaofan Yu; Yiheng Wang; Xi Li; Jun Cai
Journal:  J Transl Med       Date:  2015-06-13       Impact factor: 5.531

9.  Saquinavir Ameliorates Liver Warm Ischemia-Reperfusion-Induced Lung Injury via HMGB-1- and P38/JNK-Mediated TLR-4-Dependent Signaling Pathways.

Authors:  Zhuang Yu; Yao Tong; Renlingzi Zhang; Xibing Ding; Quan Li
Journal:  Mediators Inflamm       Date:  2017-12-26       Impact factor: 4.711

10.  Dexmedetomidine attenuates lung apoptosis induced by renal ischemia-reperfusion injury through α2AR/PI3K/Akt pathway.

Authors:  Juanjuan Li; Qian Chen; Xinhai He; Azeem Alam; Jiaolin Ning; Bin Yi; Kaizhi Lu; Jianteng Gu
Journal:  J Transl Med       Date:  2018-03-23       Impact factor: 5.531

View more
  2 in total

Review 1.  Role of Caveolin-1 in Sepsis - A Mini-Review.

Authors:  Pamella Silva Lannes-Costa; Bruna Alves da Silva Pimentel; Prescilla Emy Nagao
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

2.  Salvianolic acid A alleviates lipopolysaccharide-induced disseminated intravascular coagulation by inhibiting complement activation.

Authors:  Qi-Yun Zhang; Jing Guo; Lin Xu; Ying Wei; Shu-Ting Zhou; Qing-Yu Lu; Li Guo; Qian-Yun Sun
Journal:  BMC Complement Med Ther       Date:  2022-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.